At a glance
ClinicalIndex Comparison RecordPhase 2Active· 32 enrolled
Drug / intervention
Olaparib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Academic and Community Cancer Research United·interventional·Posted Aug 2, 2019·Updated May 15, 2026
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Computed Tomography, and 2 other interventions for Bile Duct Adenocarcinoma and 3 related conditions. Active but no longer recruiting, targeting 32 participants across 5 sites.
Detailed Summary
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
2020202120222023202420252026
First PostedAug 2019
Enrollment StartJun 2020
Primary CompletionMar 2025
TodayJul 2026
Study CompletionAug 2026
First PostedAug 2, 2019
Enrollment StartJun 24, 2020
Primary CompletionMar 12, 2025
Study CompletionAug 30, 2026
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 6.9 years ago
Interventions
Biospecimen Collectionprocedure
Undergo collection of blood and tissue samples
Computed Tomographyprocedure
Undergo CT
Magnetic Resonance Imagingprocedure
Undergo MRI
Olaparibdrug
Given PO